Ignite Creation Date:
2024-07-17 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06492616
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-10
First Post:
2024-07-01
Brief Title:
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ERHER2- Early Breast Cancer With High Risk of Recurrence
Sponsor:
Stemline Therapeutics Inc
Organization:
Stemline Therapeutics Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Breast Cancer |
Keywords:
| Name | View |
|---|---|
| ELEGANT | View |
| Breast Cancer Stage II | View |
| Breast Cancer Stage III | View |
| Breast Cancer Female | View |
| Breast Cancer Male | View |
| High-Risk Breast Cancer | View |
| High Risk Breast Carcinoma | View |
| ER-positive Breast Cancer | View |
| ER-positive HER-2 Negative Breast Cancer | View |
| ER PositiveHER2 Low Breast Cancer | View |
| Breast Cancer ER HER2- | View |
| Adjuvant | View |
| Adjuvant Therapy | View |